Elicio Therapeutics, Inc.
ELTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601485
No open-market purchases or sales by Elicio Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $15.3M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Elicio Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −3 vs. Q1 2025
- Shares held
- 1.45M
- −140.9K (−8.9%) vs. Q1 2025
- Total value
- $11.2M
- +$1.38M (+14.1%) vs. Q1 2025
- New holders
- 3
- 5 more added
- Sold out
- 6
- 5 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $15.3M |
| Q1 2026 | 47 | $28.2M |
| Q4 2025 | 37 | $16.6M |
| Q3 2025 | 28 | $20.9M |
| Q2 2025 | 21 | $11.2M |
| Q1 2025 | 24 | $9.80M |
| Q4 2024 | 17 | $2.25M |
| Q3 2024 | 18 | $2.48M |
| Q2 2024 | 20 | $2.68M |
| Q1 2024 | 18 | $3.08M |
| Q4 2023 | 18 | $2.78M |
| Q3 2023 | 18 | $2.80M |
| Q2 2023 | 15 | $2.71M |
| Q1 2023 | 28 | $2.56M |
| Q4 2022 | 30 | $3.98M |
| Q3 2022 | 38 | $4.71M |
| Q2 2022 | 43 | $5.90M |
| Q1 2022 | 47 | $13.8M |
| Q4 2021 | 53 | $20.3M |
| Q3 2021 | 47 | $69.3M |
| Q2 2021 | 41 | $66.5M |
| Q1 2021 | 41 | $92.0M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Elicio Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 630,915 | $4.87M | 3.46% | 00.0% | Unchanged |
| Vanguard Group Inc | 454,619 | $3.51M | 0.00% | +132,925+41.3% | Added |
| Geode Capital Management, LLC | 120,831 | $932.9K | 0.00% | +43,364+56.0% | Added |
| Northern Trust Corp | 51,000 | $393.7K | 0.00% | −855−1.6% | Reduced |
| BlackRock, Inc. | 43,557 | $336.3K | 0.00% | +4,234+10.8% | Added |
| CM Management, LLC | 25,000 | $193.0K | 0.18% | −30,000−54.5% | Reduced |
| State Street Corp | 21,600 | $166.8K | 0.00% | 00.0% | Unchanged |
| Quantinno Capital Management LP | 20,000 | $154.4K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 17,023 | $131.4K | 0.00% | −14,338−45.7% | Reduced |
| Meyer Handelman Co | 13,899 | $107.3K | 0.00% | 00.0% | Unchanged |
| Moody Lynn & Lieberson, LLC | 10,000 | $77.2K | 0.00% | 00.0% | Unchanged |
| Wiley Bros.-Aintree Capital, LLC | 10,000 | $77.2K | 0.00% | +10,000 | New |
| Mayflower Financial Advisors, LLC | 10,000 | $77.2K | 0.01% | +10,000 | New |
| UBS Group AG | 6,023 | $46.5K | 0.00% | −15,175−71.6% | Reduced |
| Raymond James Financial Inc | 6,000 | $46.3K | 0.00% | +6,000 | New |
| CIBC Private Wealth Group, LLC | 7,000 | $42.6K | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 1,554 | $12.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,250 | $9.65K | 0.00% | +45+3.7% | Added |
| Morgan Stanley | 380 | $2.93K | 0.00% | −462−54.9% | Reduced |
| SBI Securities Co., Ltd. | 83 | $641 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 82 | $633 | 0.00% | +17+26.2% | Added |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −182,734−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −52,218−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −36,537−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −14,993−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −185−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −16−100.0% | Sold out |